Petrichor Taps Paul Sekhri, Underscoring Value of Operational Expertise

NEW YORK, NY – April 01, 2026 – In a move that highlights a significant strategic current in life sciences investment, growth investor Petrichor has appointed Paul J. Sekhri, a titan of the biotech and pharmaceutical industries, as its new Operating Partner. The appointment is more than a high-profile hire; it signals a deepening commitment to pairing capital with seasoned operational leadership to navigate the complex and high-stakes world of healthcare innovation.

Mr. Sekhri brings over 35 years of leadership experience that forms a mosaic of the entire life sciences ecosystem. His career has seen him at the helm of venture-backed startups, in the strategic engine rooms of multinational pharmaceutical giants, and in the boardrooms of cutting-edge technology companies. This appointment provides Petrichor with an invaluable resource, embedding a leader with direct, hands-on experience in building, scaling, and guiding companies through the perilous journey from lab to market.

The Operator's Edge in a Complex Field

The value Paul Sekhri brings to Petrichor is rooted in his extensive and varied operational history. Unlike a purely financial expert, Sekhri has direct experience with the challenges and triumphs of drug and therapy development. Most recently, as Chairman, President, and CEO of vTv Therapeutics, he has been steering the company toward pivotal Phase 3 trials for TTP399, a promising drug candidate for Type 1 Diabetes that has already earned Breakthrough Therapy designation from the FDA. His leadership was instrumental in securing a $25 million investment to fund this critical next stage.

Before his tenure at vTv, Sekhri was President and CEO of eGenesis, a pioneer in the field of xenotransplantation. There, he spearheaded major scientific and organizational advancements, raising over $200 million across two financing rounds to advance the company’s platform for developing gene-edited pig organs for human transplant. This experience in a frontier area of medicine underscores his ability to guide companies working on truly disruptive technologies. His resume also includes CEO roles at Lycera Corporation and Cerimon Pharmaceuticals, alongside senior strategy roles at global powerhouses like Sanofi, Teva, and Novartis.

"We have known Paul for years, and we admire his skills as a leader of life sciences companies, both as CEO and as Chairman of the Board," said Tadd Wessel, Petrichor Founder and Managing Partner, in the official announcement. Wessel emphasized that Sekhri's "deep experience and distinguished track record... further strengthen our ability to identify and support emerging and leading healthcare innovators."

This direct operational acumen is what portfolio companies crave and what investors increasingly recognize as a key differentiator. It translates to superior due diligence, more insightful strategic guidance on clinical trial design, regulatory pathways, and commercial launch strategies, ultimately de-risking investments and accelerating growth.

Beyond Capital: A New Investment Paradigm

Sekhri's appointment is emblematic of a broader trend within private equity and venture capital, especially in highly specialized sectors like life sciences. The traditional model of simply providing capital is no longer sufficient. Today, the most effective investment partners are those who can offer a "value-add" that extends into strategy, operations, and network access. The role of an Operating Partner is the formalization of this evolution.

This is not Sekhri's first time in such a capacity. He previously served as an Operating Partner at TPG Biotech, where he was responsible for a portfolio of over 50 companies. The model is proven: embed veteran executives within the investment firm to act as mentors, problem-solvers, and strategic guides for the companies the fund backs. For life sciences, where timelines are long, capital requirements are immense, and the risk of failure is high, this hands-on approach is becoming essential.

Petrichor has built its reputation on providing customized and flexible capital solutions. By adding Sekhri, the firm is powerfully augmenting its financial offerings with invaluable intellectual and operational capital. As Sekhri himself noted, "I have seen firsthand how the Petrichor team helps innovative companies succeed in both transactional and operational settings." His decision to join the firm validates its model as a "uniquely thoughtful investor" that leverages deep team experience.

A Synergy of Networks and Knowledge

An executive's value is often measured by their network, and Sekhri’s is both broad and deep. His current board positions create a web of potential synergies for Petrichor and its portfolio. He serves as Chairman of Resolution Therapeutics, a cell therapy company, and Executive Chairman of Violet Therapeutics, which uses novel platforms to identify drug targets for neurodegenerative diseases. He also sits on the boards of Veeva Systems, a dominant force in cloud-based software for the life sciences industry, and global biopharma company Ipsen, among others.

This collection of roles provides a panoramic view of the healthcare landscape. It offers Petrichor a direct line of sight into emerging therapeutic modalities like cell therapy, early-stage discovery platforms in neurology, and the critical digital infrastructure that underpins modern R&D and commercialization. This vantage point can inform investment strategy, facilitate partnerships, and provide portfolio companies with access to an unparalleled ecosystem of expertise and opportunity. His involvement in the arts, including serving as Chairman of the Board for Young Concert Artists, also speaks to a well-rounded perspective on innovation and nurturing talent, whether in a concert hall or a research lab.

With this move, Sekhri transitions from leading individual companies to catalyzing growth across an entire portfolio. His role will be to help Petrichor identify the next generation of innovators and provide them with the strategic guidance necessary to turn scientific promise into patient reality. For entrepreneurs and management teams, the prospect of having a leader of Sekhri's caliber as an active partner is a compelling proposition, likely making Petrichor an even more attractive source of capital. This appointment reinforces the idea that in the modern investment landscape, the most valuable currency is not just money, but wisdom.